31 results about "Chlidanthine" patented technology

The invention relates to an extraction method of high-purity coptis total alkaloid, which comprises the following steps: preparing a raw material (coptis or coptis fibril or coptis ash), pulverizing (not required if the raw material is coptis fibril or coptis ash), immersing in 0.1-5% sulfuric acid, heating and extracting four times, filtering, neutralizing with calcium oxide (or calcium hydroxide), filtering, washing the precipitate, preconcentrating, regulating the acid, precipitating with sodium chloride, filtering, recovering alkaloid from the mother liquor, and drying the precipitate to obtain the coptis total alkaloid product. The main active components of the product are coptis effective components, such as berberine, coptisine, palmatine, epiberberine, jateorhizine and the like; the coptis total alkaloid content is more than 50%; and the berberine content is more than 25%. The product provided by the invention has favorable actions of lowering blood sugar and blood fat, losing weight and the like, and is an ideal raw material for treating diabetes and cardiovascular diseases.

The present invention relates to a cooling agent, and medicated ice-bag with said cooling agent and its application method. The cooling agent of said medicated ice-bag is a compound liquor whose composition contains (by volume ratio) 20% of absolute ethyl alcohol, 10% of glycerol, 20% of calcium chloride, 10% of sodium chloride, 1% of berberine and 39% of water. It does not ice at 55 deg.C below zero, and it is made into a flocculent material, its thermal eapacity is 2 calorie / g / deg.C, and it can absorb lots of heat quantity.

The invention discloses a derivant of kutkin with chemical structural formula as formula I, wherein R1 is NO2, NH2 or amide; R2 is H, carbonyl or diaminocarbonyl. The preparing method comprises the following steps: nitrating kutkin to obtain kutkin derivant substituted by nitro group or kutkin derivant based on substituted nitro group; or kutkin derivant substituted by acetylamino.

The invention discloses a feature-beautification and skin-care product and a medicinal composition for treating a burn and a scald. The medicinal composition is prepared from the following componentsof polyglutamic acid, ceramide, niacinamide, vitamin E, berberine, a calcium hydroxide saturated aqueous solution, oleum camelliae, radix sanguisorbae powder, borneol, borax and the balance of ointment. Through clinical application and observation, the medicinal composition has the effects of quickly dispersing a swelling and relieving pain for positions suffering from the burn and the scald and promoting a wound surface to heal, effectively inhibiting bacteria on the wound surface from breeding and preventing cross infection. Meanwhile, in a process of treating tissue suffering from the burnand the scald, a skin is promoted to be repaired at the same time; the formation of scars is reduced; further, an untoward effect does not exist; particularly, after wound surfaces of large-area burnand scald are treated, marks of the scars of the treated skin are light in color, and in a condition that the feature-beautification and skin-care product provided by the invention is insistently used, the scars of the burn and the scald can be eliminated.

The invention relates to a derivative of Kutkin dimer analog JJA-D0 or its pharmaceutically acceptable salt, a preparation method and use thereof. The compound has a structure shown as a general formula (I). According to the invention, an alkyl group, an aryl group, a heteroaryl group, an alkoxycarbonylalkyl group, an acyl group, a sulfonate group, an antioxidant group such as a lipoic acid group,a H2S donor group such as a cysteine group, and a NO donor group such as a nitrate group are introduced to JJA-D0, and a series of structurally novel compounds can be synthesized and disclosed. The compounds inhibit NADPH oxidase and have superior anti-oxidation and anti-inflammatory pharmacological mechanisms by comparing with Kutkin, the compounds also have donor groups that provide NO and H2S,can further enhance pharmacological activity, and can be a new class of multifunctional compounds. The disclosed JJA-D0 derivative can be used for preparing health products or drugs for prevention ortreatment of diseases associated with NADPH oxidase, diseases associated with free radicals, diseases associated with inflammation, diseases associated with NO, and diseases associated with H2S.

The invention discloses an application of berberine in preparing a drug for treating sterility of ovulation disturbance. Studies show that berberine can promote ovulation of a patient suffering from infertility of ovulation disturbance; and during a treatment process, the probability of twins and triplets is far lower than that of an ovulation induction drug of clomiphene, thereby greatly reducing risks of multiple pregnancy and occurrence of pregnancy complications, and reducing occurrence of adverse reactions. Besides, the drug is cheap and can be accepted by the patient easily. The drug is attractive in price and quality and is worth of popularization and application. Therefore, the application of berberine in preparing the drug for treating the sterility of ovulation disturbance is provided by the invention. The novel curative effect becomes a novel indication of berberine, broadens clinical application capacity of berberine, and will achieve enormous social benefits and economic benefits.

The invention relates to a combination drug used for killing genitals microorganisms of female Tibetan mastiffs and assisting reproduction. The combination drug contains matrine, podophyllotoxin, berberine, vitamin C, etoposide and antifungal drugs in western medicine.

The invention discloses an anti-inflammatory medicament capable of treating beriberi and a preparation method thereof. The anti-inflammatory medicament is prepared from the following raw materials by weight percent: 2-10% of oxytetracycline, 2-10% of berberine, 2-10% of compound sulfanilamide dimethyl, 2-10% of analgin, 8-16% of paracetamol caffeine aspirin powder, 2-10% of norfloxacin, and 40-80% of traditional Chinese medicine mixed liquor, wherein the traditional Chinese medicine mixed liquor comprises the following components in parts by weight: 50-100 parts of eggplant stem, 20-50 parts of pepper stem, 70-100 parts of peanut shell, 30-60 parts of sunflower seed shell, 20-40 parts of towel gourd seedling, 10-30 parts of almond shell and 30-50 parts of scandent hop, and is prepared through dipping cook by 4000-6000 parts of water and filtering. The anti-inflammatory medicament combines the traditional Chinese medicine and western medicine, can be used for effectively reducing foot fungus, eliminating fungal infection, relieving pain and itching, and getting rid of foot odor, becomes effective rapidly, and has high cure rate.

The invention relates to an acne removing lotion, an acne removing medicine composition and a preparation method of the acne removing medicine composition. Effective components of the acne removing lotion are prepared from the following raw materials in parts by weight: 15 to 25 parts of meleumycin, 5 to 15 parts of vitamin, 15 to 25 parts of chloramphenicol, 5 to 15 parts of berberine and 15 to 25 parts of ethanol. According to the acne removing lotion and the acne removing medicine composition disclosed by the invention, clogged pores can be quickly dredged, further skin endotoxins are discharged out of the body through the dredge pores to kill skin bacteria, the cell activity is stimulated for detoxification and promotion of tissue regeneration, so that acnes are thoroughly removed, and the skin becomes fine and glossy, smooth and white-skinned, and no acne scars are formed.

The invention provides a silver ion no-wash disinfectant as well as a preparation method and application thereof. The silver ion no-wash disinfectant is prepared from the following raw materials in percentage by weight: 50 to 70 percent of absolute ethyl alcohol, 0.001 to 0.05 percent of silver nitrate, 1 to 10 percent of rhizoma coptidis extracting solution, 0.5 to 5 percent of stabilizer, 0.01 to 1 percent of pH regulator, 0.1 to 2 percent of thickener, 1 to 5 percent of humectant and the balance of water, wherein the coptis chinensis extract contains berberine, and the concentration of the berberine in the washing-free disinfectant is 0.1 mg / mL to 1 mg / mL. The no-clean disinfectant disclosed by the invention has the advantages of safety, good sterilization and bacteriostasis effects, difficulty in generating drug resistance and the like.

The invention relates to the medicine and the preparation method for treating the psoriasis. The invention delivers the smashed ripe nuts of hydnocarpus and fructus bruceae, powdered Yisaoguang, a smashed berberine tablet without the sugar-coat or the berberine liquid medicine, peeled and mashed garlic and the edible vinegar essence under the normal temperature of 17-22 DEG C into a container according to the ratios of weights of four point zero-four point five to zero point thirty five-zero point fifty five to zero point two-zero point four to zero point fifty five-zero point seventy five to ten-eleven to forty eight-fifty two, and then the materials are soaked under the closed condition, after two hours of soaking, the liquid is exactly the drug for external application.

The invention discloses a composite callus ointment. The composite callus ointment is characterized by being prepared from the following components by ratio: 6.7% of oxytetracycline, 6.7% of berberine, 6.7% of Yunnan Baiyao, 3.3% of metronidazole, 3.3% of vitamin C, 3.3% of cimetidine, 2.3% of complex vitamin B, 1% of borneol and 66.7% of vaseline. The problems that an existing external ointment is poor in treatment effect on pain and itching caused by anorectal disease and chapped skin is solved; and the composite callus ointment is suitable for being smeared by patients with anal pruritus, anal fissure and chapped skin.

The invention relates to an external ulcer powder, which is characterized by including: 15% of oxytetracycline, 15% of berberine, 10% of compound sulfamethoxazole, 10% of metronidazole, 15% of composite vitamin B, 15% of vitamin C, 10% of cimetidine, 7% of calcium, and 3% of chlorpheniramine. The external ulcer powder provided by the invention solves the problem that existing external ulcer powder is inapplicable to treatment of bedsore and other skin mucosa ulcer, scalds, non healing wounds and other diseases, and is suitable for treatment of various infantile febrile convulsion patients.

The present invention relates to derivatives of berberine dimer analog JJA-D0 or pharmaceutically acceptable salts, preparation methods and uses thereof. The compound has the structure of general formula (I). The present invention introduces hydrocarbon groups, aryl groups, heteroaryl groups, alkoxycarbonyl groups, acyl groups, sulfonate groups, antioxidant groups such as lipoic acid groups, H 2 S donor groups such as cysteinyl, NO donor groups such as nitrate groups, etc., synthesized and disclosed a series of compounds with new structures. These compounds can inhibit NADPH oxidase, and have a better anti-oxidation and anti-inflammatory dual pharmacological mechanism than berberine. Some of these compounds can also provide NO, H 2 The donor group of S can further enhance the pharmacological activity, and it is a new class of multifunctional compound. The disclosed JJA-D0 derivatives can be used to prevent or treat diseases related to NADPH oxidase, diseases related to free radicals, diseases related to inflammation, diseases related to NO, diseases related to H 2 Preparation of health products or medicines for S-related diseases.

The invention discloses a method for purifying berberine or its hydrochloride, which comprises: mainly including the reaction of the starting material mainly containing berberine, berberine hydrochloride or berberine sulfate with salt II, and converting it into an intermediate salt of berberine, Finally, the intermediate salt of berberine is converted into berberine or its hydrochloride. The present invention converts the starting material mainly containing berberine, berberine hydrochloride or berberine sulfate into an intermediate salt of berberine, removes impurities, and then converts the intermediate salt of berberine into berberine or its hydrochloride, The final product has a total impurity content of less than 0.2% and a single impurity content of less than 0.1%, which further ensures the safety of the drug.

The invention belongs to the field of medical intermediate detection, and particularly discloses a high performance liquid chromatography detection method of berberine intermediates, the intermediates are homopiperony lamine, the chemical name is 3, 4-methylenedioxy phenylethylamine, and the detection method comprises the steps of determination of chromatographic conditions, preparation of a test solution, preparation of a reference solution and preparation of a standard substance. Calculating a standard curve; respectively and precisely measuring the test solution and the reference solution, injecting into a liquid chromatograph, recording a chromatogram, and calculating the content by peak area according to an external standard method. The detection method disclosed by the invention is good in specificity, high in sensitivity and high in separation degree, and durability, linearity and the like can meet requirements.

The invention relates to a berberine anti-tumor platinum (II) complex, its synthesis method and the application of the complex in the preparation of anti-tumor drugs. The synthesis method of the berberine anti-tumor platinum (II) complex comprises the following steps: (1) dissolving the brominated berberine derivative, potassium halide and lutidine amine in a solvent, and reacting at 90° C. to obtain B ‑TFA ligand; (2) the B‑TFA ligand prepared in step (1) and dichlorobis(dimethylsulfoxide) platinum (II) are dissolved in acetonitrile solution, and carry out coordination reaction 4~6 Hours, the product was washed and dried to obtain. The present invention uses the brominated berberine derivative B-TFA as the active ligand for the first time to synthesize its platinum complex, which exhibits superior anti-tumor activity and targeting in vivo and in vitro, has potential medicinal value, and is expected to be used in various Preparation of antineoplastic drugs. The structural formula of the berberine anti-tumor platinum (II) complex is as follows:

Belonging to the field of drugs or health care products, the invention relates to a pharmaceutical composition for treatment of inflammatory skin diseases, in particular to a pharmaceutical composition for treatment of acnes. The pharmaceutical composition comprises the following raw materials: 8.5-11.5 parts by weight of Chinese herb Pien Tze Huang, 68-92 parts by weight of Gynura formosana, 5.1-6.9 parts by weight of hesperidin, and 3.4-4.6 parts by weight of berberine. Clinical research shows that the pharmaceutical composition not only has obvious therapeutic effect on acnes, has a clinical total effective rate up to 90%, but also can effectively improve pigmentation and scars left after acne fading, and has little adverse reaction in clinical application and high safety, thus having good clinical application prospect.

The present invention discloses a special insect disinfestation and sterilization agent for strawberry, wherein the special insect disinfestation and sterilization agent comprises, by weight, 20-30 parts of berberine, 25-36 parts of wuyiencin, 10-30 parts of metaldehyde, 11-21 parts of phoxim, 8-15 parts of dipterex, 5-8 parts of chlorpyrifos, 10-20 parts of litchi shell, and 5-15 parts of willow leaf. The invention further discloses a preparation method of the special insect disinfestation and sterilization agent. According to the present invention, by compounding the chemical reagent and the plant, the good insect disinfestation and sterilization effect is provided; through the reasonable ratio, the effective insect disinfestation and sterilization effect can be ensured, and the good economic and the ecological benefits can be obtained; the raw material source is wide, the cost low, and the insect disinfestation and sterilization agent is suitable for large area promotion application; and the special insect disinfestation and sterilization agent can be subjected to one time use from the reality so as to reduce the labor operation.

The invention relates to medicine and a preparation technology thereof, namely heat clearing and hematostatic Mongolian medicine and preparation technology thereof. The Mongolian medicine is characterized by being prepared from the following active ingredients in parts by weight: 1 to 2 parts of gardenoside, 1 to 2 parts of rutin, 1 to 2 parts of carthamin, 1 to 2 parts of beta-sitosterol, 1 to 2parts of rheum emodin, 1 to 2 parts of glycyrrhizic acid, 1 to 2 parts of kutkin, 1 to 2 parts of rubican, 1 to 2 parts of alkannin, 1 to 2 parts of shellac resin, 3 to 5 parts of calcium carbonate, 3to 5 parts of calcium phosphate, 3 to 5 parts of amino acid, 2 to 3 parts of cholic acid and 2 to 3 parts of calculus bovis. The Mongolian medicine has the beneficial effects of heat clearing, bloodcooling and hematostatic effects, obvious curative effects on hemorrhage syndromes of hematemesis, hemafecia, menorrhagia, traumatic bleeding, liver diseases and the like, low toxic and side effect, wide suitable crowd range, convenience in taking, convenience in digestion and absorption and quick effect; thus, the Mongolian medicine hopefully becomes typical medicine for treating lung diseases.

The invention discloses a method for purifying berberine or its salt, comprising: converting a raw material mainly containing berberine or berberine salt I into an acetone adduct of berberine, and then converting the acetone adduct of berberine into Berberine salt II to obtain the product berberine salt II or berberine. The invention also discloses an acetone adduct crystal form of berberine. Adopt purification method of the present invention, berberine acetone adduct is converted into berberine acetone adduct by raw material containing berberine or berberine salt, then berberine acetone adduct is converted into final product berberine or its salt, can obtain high The pure berberine or its salt has a total impurity content of less than 0.2 percent and a single impurity content of less than 0.1 percent, which ensures the safety of the drug.

The invention discloses a novel berberine derivative as well as a synthesis method and application thereof, belongs to the field of imaging agents, and aims to derive the structure of isoquinoline alkaloid berberine, optimize derived sites on the basis of an early stage and introduce an F-containing side chain to prepare a series of probes with a myocardial targeting property. A 18F marker of theseries of compounds is successfully prepared through a marking experiment of positron nuclide 18F; the 18F-labeled novel berberine derivative is higher in myocardial uptake, raw materials are easy toobtain, the synthesis cost of a molecular probe is reduced, and clinical transformation is facilitated.

The invention discloses a drug co-crystal of dihydromyricetin-berberine hydrochloride, which belongs to the technical field of drug crystallization. The present invention combines dihydromyricetin and berberine hydrochloride through intermolecular hydrogen bonding to form the dihydromyricetin-berberine hydrochloride drug eutectic. The preparation method of the invention is simple and easy, and the cost is low. The prepared dihydromyricetin-berberine hydrochloride drug eutectic structure is clear, without hygroscopicity, and the dissolution rate of dihydromyricetin and berberine hydrochloride in water is similar, and can be dissolved simultaneously, showing a synergistically enhanced effect on specific tumor cells. inhibition.

The invention discloses a derivant of kutkin with chemical structural formula as formula I, wherein R1 is NO2, NH2 or amide; R2 is H, carbonyl or diaminocarbonyl. The preparing method comprises the following steps: nitrating kutkin to obtain kutkin derivant substituted by nitro group or kutkin derivant based on substituted nitro group; or kutkin derivant substituted by acetylamino.

The invention discloses fenofibric acid salts of berberine and analogues thereof, a crystal form, a preparation method and applications thereof, wherein the fenofibric acid salt comprises fenofibric acid serving as an anion and berberine or a berberine analogue serving as a cation. According to the invention, the fenofibric acid salt of berberine or analogue thereof can be used for removing unnecessary cations from commercially available medicines, ie., choline cations in choline fenofibrate and / or chlorine ions in berberine hydrochloride, so that a certain side effect, including gastrointestinal irritation due to instability property of choline as an anion and high acidity of berberine hydrochloride, caused by the two pairing ions can be reduced.

The invention relates to an extraction method of high-purity coptis total alkaloid, which comprises the following steps: preparing a raw material (coptis or coptis fibril or coptis ash), pulverizing (not required if the raw material is coptis fibril or coptis ash), immersing in 0.1-5% sulfuric acid, heating and extracting four times, filtering, neutralizing with calcium oxide (or calcium hydroxide), filtering, washing the precipitate, preconcentrating, regulating the acid, precipitating with sodium chloride, filtering, recovering alkaloid from the mother liquor, and drying the precipitate to obtain the coptis total alkaloid product. The main active components of the product are coptis effective components, such as berberine, coptisine, palmatine, epiberberine, jateorhizine and the like; the coptis total alkaloid content is more than 50%; and the berberine content is more than 25%. The product provided by the invention has favorable actions of lowering blood sugar and blood fat, losing weight and the like, and is an ideal raw material for treating diabetes and cardiovascular diseases.

The invention relates to a natural pharmaceutical composition, and a preparation method and application thereof. The natural pharmaceutical composition is composed of 2-7 parts of coptis / cinnamon water decoction concentrated extract, 3-7 parts of berberine and 4-6 parts of cinnamaldehyde. The composition has favorable curative effect on cancer chemotherapy related diarrhoea.

The invention provides an anti- P.aeruginosa pharmaceutical composition as well as a preparation method and application thereof. The pharmaceutical composition comprises the following components: (1)berberine and / or halogenated berberine, and (2) 3, 4-dibromomaleimide. Compared with single use of the berberine or the halogenated berberine for resisting P.aeruginosa, the anti- P.aeruginosa pharmaceutical composition has the advantages that after the berberine, the halogenated berberine and the 3, 4-dibromomaleimide adjuvant are compatible, the anti- P.aeruginosa activity of the pharmaceuticalcomposition can be improved by 4 times or above compared with that of raw medicines (the berberine and the halogenated berberine). Due to the fact that the dosage of raw medicines is greatly reduced,the content of the medicines of the berberine and the halogenated berberine contained in the novel preparation can be reduced by 4 times or above compared with the concentration of the raw medicines,and toxicity and various adverse reactions caused by high-dosage medication of various berberine and halogenated berberine are effectively avoided.

The invention discloses a folic acid-berberine self-assembled targeting nano-drug and a preparation method thereof. Folic acid-berberine nano-drug molecules are prepared by designing the preparation method, self-assembly of indissolvable drugs is realized, and the water-soluble targeting nano-drug is obtained. The invention provides the preparation method of the folic acid-berberine nano-drug andapplication of the nano-drug in cancer treatment. The folic acid-berberine nano-drug provided by the invention has specific antibody response, can realize targeted drug release of the drug at a tumorsite, and has the advantages of being low in cost, high in stability, free of immunogenicity, capable of reducing toxicity accumulation and drug resistance, capable of exerting a good treatment effectdue to the low drug loading capacity and capable of being selectively delivered to tumor tissues.